Johnson & Johnson (JNJ) Inventory (2009 - 2026)
Johnson & Johnson (JNJ) posted Inventory of $15.1 billion for Q2 2026, up 3.85% sequentially from $14.6 billion in Q1 2026, and up 12.91% YoY from $13.4 billion in Q2 2025.
Johnson & Johnson (JNJ) Inventory (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Inventory for 18 years, with the latest figure at $15.1 billion in Q2 2026.
- Quarterly Inventory rose 12.91% year-over-year to $15.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $15.1 billion (up 12.91% YoY) and the FY2025 annual result came in at $14.2 billion, up 14.04% from the prior year.
- Inventory rose to $15.1 billion in Q2 2026 per JNJ's latest filing, from $14.6 billion in the prior quarter.
- Over five years, Inventory peaked at $15.1 billion in Q2 2026 and troughed at $10.3 billion in Q1 2023.
- A 5-year average of $12.4 billion and a median of $12.4 billion in 2024 frame the typical range for Inventory.
- The sharpest annual moves came in 2023 and 2024: Inventory advanced 16.55% in 2023, then retreated 11.13% in 2024.
- Over 5 years, Inventory stood at $11.7 billion in 2022, then dropped by 4.23% to $11.2 billion in 2023, then rose by 11.3% to $12.4 billion in 2024, then advanced by 14.04% to $14.2 billion in 2025, then climbed by 6.72% to $15.1 billion in 2026.
- According to Business Quant data, Inventory over the past three periods registered $15.1 billion, $14.6 billion, and $14.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.29 Bn | 631.53 Bn | 17.26 Bn | 15.14 Bn |
| 2 | AbbVie | 469.70 Bn | 463.14 Bn | 12.70 Bn | 5.13 Bn |
| 3 | Merck | 374.92 Bn | 367.78 Bn | 12.21 Bn | 6.21 Bn |
| 4 | Novartis Ag | 302.99 Bn | 295.30 Bn | 11.24 Bn | 6.22 Bn |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn | 6.93 Bn |
| 6 | Amgen | 236.63 Bn | 222.64 Bn | 7.24 Bn | 6.22 Bn |
| 7 | Gilead Sciences | 182.46 Bn | 179.28 Bn | 6.22 Bn | 1.95 Bn |
| 8 | Pfizer | 159.59 Bn | 147.89 Bn | 10.94 Bn | 9.95 Bn |
| 9 | Gsk | 106.12 Bn | 101.95 Bn | 8.24 Bn | 8.43 Bn |
| 10 | Sanofi | 55.21 Bn | 47.83 Bn | 10.79 Bn | 12.93 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 15.14 Bn |
| Mar 29, 2026 | 14.58 Bn |
| Dec 28, 2025 | 14.19 Bn |
| Sep 28, 2025 | 14.15 Bn |
| Jun 29, 2025 | 13.41 Bn |
| Mar 30, 2025 | 12.66 Bn |
| Dec 29, 2024 | 12.44 Bn |
| Sep 29, 2024 | 12.60 Bn |
| Jun 30, 2024 | 12.17 Bn |
| Mar 31, 2024 | 11.38 Bn |
| Dec 31, 2023 | 11.18 Bn |
| Oct 1, 2023 | 11.20 Bn |
| Jul 2, 2023 | 12.89 Bn |
| Apr 2, 2023 | 12.81 Bn |
| Jan 1, 2023 | 10.27 Bn |
| Oct 2, 2022 | 11.68 Bn |
| Jul 3, 2022 | 11.44 Bn |
| Apr 3, 2022 | 10.99 Bn |
| Jan 2, 2022 | 10.39 Bn |
| Oct 3, 2021 | 10.39 Bn |